Re: Farmas USA
Wednesday, September 19, 9:01 AM Deutsche Bank initiates coverage of Achillion (ACHN +12.35% to $9.10) with a "Buy" and gives the company a price target of $12, saying it's unpartnered and under-appreciated. Deutsche Bank is confident about Achillion's hepatitus C drugs, and said it could be a takeover target. Meanwhile, BofA upgrades Achillion to a "Buy" from "Underperform."
ACHN